Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Accounts Payables: 2022-2024

Historic Accounts Payables for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $13.6 million.

  • NewAmsterdam Pharma Co N.V's Accounts Payables fell 4.56% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 4.56%. This contributed to the annual value of $13.6 million for FY2024, which is 19.59% down from last year.
  • As of FY2024, NewAmsterdam Pharma Co N.V's Accounts Payables stood at $13.6 million, which was down 19.59% from $16.9 million recorded in FY2023.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Accounts Payables registered a high of $16.9 million during FY2023, and its lowest value of $11.9 million during FY2022.
  • Its 3-year average for Accounts Payables is $14.1 million, with a median of $13.6 million in 2024.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Accounts Payables skyrocketed by 42.77% in 2023 and then declined by 19.59% in 2024.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's Accounts Payables (Yearly) stood at $11.9 million in 2022, then spiked by 42.77% to $16.9 million in 2023, then decreased by 19.59% to $13.6 million in 2024.